The fusion of Clario's innovative endpoint technologies and CellCarta's sample management expertise offers a single-vendor solution for imaging and histopathology in clinical trials, advancing industry standards.

Clario创新终点技术与CellCarta样品管理专业知识的融合为临床试验中的成像和组织病理学提供了单一供应商解决方案，提高了行业标准。

Clario and CellCarta's strategic partnership enhances clinical trial sample handling and digitization within Clario's web-based 21 CFR Part 11 compliant platform.

Clario和CellCarta的战略合作伙伴关系增强了Clario基于网络的21 CFR Part 11兼容平台内的临床试验样品处理和数字化。

This collaboration streamlines tissue and biopsy sample logistics across multiple therapeutic areas, increasing accessibility for pathology-related trials.

这种合作简化了多个治疗领域的组织和活检样本物流，增加了病理相关试验的可及性。

Offering a single-vendor solution for imaging and pathology in clinical trials that provides end-to-end visibility for sample management, automated transfer of digitized pathology images and accelerated centralized assessments.

为临床试验中的成像和病理学提供单一供应商解决方案，为样品管理提供端到端的可见性，数字化病理图像的自动传输和加速集中评估。

PHILADELPHIA, Sept. 26, 2023 /PRNewswire/ -- Clario, a healthcare research technology company that delivers the leading endpoint technology solutions for clinical trials, proudly announces a strategic partnership with CellCarta, experts in integrated sample management and specialized laboratory services.

费城，2023年9月26日/PRNewswire/-Clario是一家医疗保健研究技术公司，为临床试验提供领先的终点技术解决方案，自豪地宣布与CellCarta，综合样本管理和专业实验室服务专家的战略合作关系。

Together, Clario and CellCarta are set to make significant strides in improving clinical trial sample handling, ensuring seamless operations and unprecedented access within Clario's innovative platform..

Clario和CellCarta将共同努力，在改进临床试验样品处理方面取得重大进展，确保在Clario的创新平台内实现无缝操作和前所未有的访问。。

This partnership aims to streamline the handling of tissue and samples and subsequent digitization in support of clinical trial endpoint generation across multiple therapeutic areas, including oncology, hepatology (e.g., NASH), and gastroenterology (e.g., UC and Crohn's). The collaboration also provides several options for sites to submit pathology data/samples, including fixed tissue, tissue blocks, glass slides or whole slide images.

该合作伙伴关系旨在简化组织和样品的处理以及随后的数字化，以支持跨多个治疗领域（包括肿瘤学，肝病学（例如NASH）和胃肠病学（例如UC和克罗恩氏病））的临床试验终点生成。该合作还为网站提交病理数据/样本提供了多种选择，包括固定组织，组织块，载玻片或整个载玻片图像。

This flexibility increases the number of sites that could potentially participate in pathology-related trials, removing limitations surrounding the availability of local histopathology support staff or equipment. Additionally, due to CellCarta's detailed SOPs (standard operating procedures), maintained across their multiple geographic locations, samples are processed and digitized in a consistent manner using certified equipment, reducing potential quality issues and minimizing variability in centralized assessments..

这种灵活性增加了可能参与病理相关试验的部位数量，消除了当地组织病理学支持人员或设备可用性的限制。此外，由于CellCarta的详细SOP（标准操作程序）在多个地理位置进行维护，因此使用经过认证的设备以一致的方式处理和数字化样品，减少潜在的质量问题并最大限度地减少集中评估的可变性。。

'This collaboration brings together Clario's cutting-edge scientific expertise and unrivaled clinical trial endpoint solutions with CellCarta's unparalleled sample processing and management expertise,' noted Dr. Joyce Suhy, Executive Vice President, Medical Imaging and Specialty Solutions at Clario.

Clario医学成像和专业解决方案执行副总裁Joyce Suhy博士指出：“这项合作将Clario的尖端科学专业知识和无与伦比的临床试验终点解决方案与CellCarta无与伦比的样品处理和管理专业知识结合在一起。

'This partnership advances Clario's ability to support histopathology studies, providing our customers with full visibility for biopsy sample logistics and significantly accelerates delivery of centralized assessments for eligibility and efficacy endpoints.'.

“这种合作关系提高了Clario支持组织病理学研究的能力，为我们的客户提供了活检样本物流的全面可见性，并显着加速了对资格和功效终点的集中评估。

CellCarta's clinical trial sample management offers kit provisioning and sample accessioning, processing, digitization, and quality control. Features such as the automated and secure transfer of digitized pathology images from the CellCarta portal to the Clario portal avoid delays related to manual download and upload.

CellCarta的临床试验样品管理提供试剂盒供应和样品采集，处理，数字化和质量控制。从CellCarta门户到Clario门户的数字化病理图像的自动安全传输等功能避免了与手动下载和上传相关的延迟。

Additionally, the review of whole slide images occurs within the Clario web-based 21 CFR Part 11 compliant platform, eliminating the need to download and review in a 3rd party software and providing accelerated centralized assessments..

此外，整个幻灯片图像的审查发生在基于Clario web的21 CFR Part 11兼容平台内，无需在第三方软件中下载和审查，并提供加速的集中评估。。

The fusion of Clario's healthcare research technology and scientific expertise with CellCarta's specialized precision medicine laboratory services significantly improve Clario's ability to support histopathology studies. Customers no longer need to contract with multiple vendors for studies that require pathology; Clario can support assessments from MRI, CT, PET, etc., and pathology within a single platform for a given study.

Clario的医疗保健研究技术和科学专业知识与CellCarta专业精准医学实验室服务的融合显着提高了Clario支持组织病理学研究的能力。客户不再需要与多个供应商签订需要病理学研究的合同；Clario可以在给定研究的单个平台内支持MRI，CT，PET等的评估和病理学评估。

With a global footprint and the capacity for regional support, this partnership empowers customers with comprehensive, single-vendor solutions that transcend industry standards..

凭借全球足迹和区域支持能力，这种合作关系为客户提供超越行业标准的全面，单一供应商解决方案。。

To explore the future of clinical trial sample management and learn more about Clario's transformative healthcare research technology, visit Clario.com.

要探索临床试验样本管理的未来，并更多地了解Clario的转型医疗保健研究技术，请访问Clario.com。

About ClarioClario is a leading healthcare research and technology company that generates the richest clinical evidence in the industry for our pharmaceutical, biotech and medical device partners. Across decentralized, hybrid and site-based trials, our deep scientific expertise, global scale and the broadest endpoint technology platform in the industry allows our partners to transform lives.

关于ClarioClario是一家领先的医疗保健研究和技术公司，为我们的制药，生物技术和医疗器械合作伙伴提供行业中最丰富的临床证据。通过分散，混合和基于现场的试验，我们深入的科学专业知识，全球规模和行业最广泛的终点技术平台使我们的合作伙伴能够改变生活。

Clario has the only technology platform that combines eCOA, cardiac safety, medical imaging, precision motion, and respiratory endpoints. With 30 facilities in nine countries, Clario's global team of science, technology and operational experts has helped deliver over 19,000 trials and 870 regulatory approvals for over five million patients in 120 countries.

Clario是唯一结合eCOA，心脏安全，医学成像，精确运动和呼吸终点的技术平台。Clario的全球科学，技术和运营专家团队在9个国家拥有30个设施，帮助为120个国家的500多万患者提供了19000多项试验和870项监管批准。

Our innovation has been transforming clinical trials for 50 years..

我们的创新已经改变了临床试验50年。。

For more information, go to Clario.com or follow us on LinkedIn and Twitter

欲了解更多信息，请访问Clario.com或在LinkedIn和Twitter上关注我们

Clario Media ContactDuncan CantorSr. Director, Corporate Communications[email protected]

Clario Media ContactDuncan CantorSr。公司通讯总监[电子邮件保护]

Logo - https://mma.prnewswire.com/media/1677749/Clario_Logo.jpg

徽标-https://mma.prnewswire.com/media/1677749/Clario_Logo.jpg

SOURCE Clario

源Clario